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Abstract
Background: The CTLA4 (cytotoxic T-lymphocyte antigen 4) gene is associated with several immunopathologic 
diseases and because of its important immuno-regulatory role it may be considered also a plausible candidate for a 
genetic association with inflammatory bowel diseases. Previously published studies found no association of CTLA4 with 
Crohn's disease itself, but some indicated an association with its subphenotypes. The aim of this study was to assess 
the association in the Czech population, using a set of markers shown to associate with other diseases.
Methods: Six polymorphisms within the CTLA4 region were investigated in 333 patients with Crohn's disease and 482 
unrelated healthy controls, all Caucasians of Czech origin. The genotypes of the SNPs were determined using the 
TaqMan SNP genotyping assays. Haplotypes were reconstructed using an expectation-maximization algorithm, and 
their association with the condition was assessed using log-linear modeling. Then, potential interactions were tested 
between the CTLA4 variants and other genetic factors known to confer the disease susceptibility.
Results: No crude associations with Crohn's disease were found for the tested CTLA4 variants under the log-additive or 
dominant models. However, when stratified for the genetic risk conferred by the variants in the NOD2 (the 
p.Leu1007fsX1008, rs5743293) or the IL23R (p.R381Q, rs11209026), a significant negative association emerged for the 
minor alleles of CTLA4 CT60 (rs3087243), JO31 (rs11571302), JO27-1 (rs11571297) polymorphisms. This negative 
association with CTLA4 was apparent only in the strata defined by presence minor alleles at the NOD2 rs5743293 (here 
the CTLA4 CT60 A coffered an OR = 0.43, 95%CI 0.19 - 0.95 for the presence of CT60 A), or IL23R rs11209026 (here the OR 
for presence of CT60 A was 0.23, 95%CI 0.07 - 0.71). We observed this effect also for the haplotype consisting of minor 
alleles of the three tightly linked CTLA4 markers. Furthermore, this haplotype was associated with the younger age at 
diagnosis (OR 1.52, 95%CI 1.09 - 2.11, p = 0.014).
Conclusions: A protective effect of a CTLA4 haplotype was unmasked after stratification for the risk variants in the 
NOD2 and IL23R genes, and may point towards the biological relevance of the molecule in the pathogenesis of the 
disease.
Background
Crohn's disease (CD) belongs to inflammatory bowel dis-
eases (IBD) that are characterized by chronic, relapsing
and recurrent inflammation of intestinal mucosa. The
disease is thought to result from the action of environ-
mental factors in genetically susceptible individuals.
Three variants in the NOD2 [1,2], IBD5 locus [3] and one
variant in the IL23R [4] and in the ATG16L1  [5] have
been independently confirmed to be associated with CD,
including associations found previously in the Czech
population [6,7]. Recent studies, however, show that this
list is far from being complete [5,8-12].
The CTLA4 gene may also be considered as a plausible
candidate for a genetic association with IBD. Its product,
the cytotoxic T-lymphocyte-associated protein 4
(CTLA4) is a T-cell suppressor which plays an essential
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role in the function of the CD25(+)CD4(+) regulatory
cells that control the process of intestinal inflammation
[13,14]. The CTLA4 gene maps within the 2q33 region
that has been found to carry suggestive linkage signifi-
cance for IBD [15]. The CTLA4 gene is associated with
other immunopathologic diseases (type 1 diabetes,
Graves' disease, Addison's disease, celiac disease, sys-
temic lupus erythematosus, rheumatoid arthritis, vitiligo)
[16]. Among the studied single nucleotide polymor-
phisms (SNPs), the CT60 (rs3087243) shows the most
prominent associations, being followed by other three
SNPs: JO31 (rs11571302), JO30 (rs7565213) and JO27-1
(rs11571297) [16]. A recent publication has shown evi-
dence for association of another SNP within the CTLA4
with type 1 diabetes, the rs1427676 [17]. Previously pub-
lished papers about genetic association with CD tested
three variants in the CTLA4 gene: g.49A > G (rs231775),
g.-318C > T (rs5742909) and the previously mentioned
CT60, having found no association [18-21]. However,
several works suggested that CTLA4 variants may influ-
ence the phenotype of CD [18,19].
The aim of this study was to assess the association in
the Czech population, using a set of markers previously
shown to associate with other diseases.
Methods
Subjects
In a case-control design, 333 Czech patients were com-
pared to 482 unrelated healthy Czech controls represent-
ing a general population sample from the same
geographical region. We tested 137 pediatric-onset
patients (71 boys, 66 girls) who developed CD under or at
the age of 18 years and were diagnosed according to the
Porto criteria [22], and 196 adult onset patients (77
males, 119 females) diagnosed according to endoscopic,
radiological, histological and clinical criteria. Phenotypic
classification was done according to the Montreal Classi-
fication [23]. The demographic and clinical characteris-
tics of the patients are listed in Table 1 and Table 2. The
control group included 482 individuals: 295 children, 187
adult; 311 males, 171 females; median age 12 years, inter-
quartile range 7-34 years. The study was approved by the
Ethics Committees of the authors' institutions, and a
written informed consent was obtained from all partici-
pants or their guardians.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes with a routine salting out method, or from sali-
vary samples using Oragene DNA Self-Collection Kit
according the manufacturer's protocol (DNA Genotek
Inc., Ottawa, Ontario, Canada). One SNP proximal to
CTLA4 (rs736611), one from within the gene (g.49G > A,
rs231775), and four SNPs located distally from the coding
part of CTLA4  gene (rs3087243 also called CT60;
rs11571302 called JO31; rs11571297 called JO27-1; and
rs1427676) were selected based on available literature
and genotyped using the TaqMan SNP genotyping assays
(TaqMan SNP Genotyping Assay by Applied Biosystems,
Foster City, CA, USA). The assays were run on an ABI
7300 machine (Applied Biosystems, Foster City, CA,
USA) and evaluated according to manufacturer's instruc-
tions. To ensure consistency between runs, samples of
known genotypes were repeated in every analysis. For
testing interactions with other associated genes, we used
genotypes generated in previously published studies on
this sample set [6,7].
Statistical analysis
The Hardy-Weinberg equilibrium was checked by com-
paring observed to expected genotype frequencies in the
control subjects, and tested using exact tests. Associa-
tions of particular SNPs with CD were evaluated using
odds ratios (OR) with 95% confidence intervals (CI). Hap-
lotype analysis was performed by estimating the haplo-
type frequencies by the expectation-maximization
algorithm implemented in the R-project package
'haplo.stats' version 1.3.1. Association of haplotypes with
the conditions was tested using log-linear modeling.
Then, a potential interaction between the CTLA4 vari-
ants and other genetic factors associated with the autoim-
mune conditions were tested. The statistical analysis was
performed using the R-project package 'SNPassoc' ver-
sion 1.5-2 [24].
Table 1: Demographic characteristics of patients and control subjects
CD patients Control subjects (n = 482)
Total (n = 333) Pediatric-onset CD (n = 137) Adult-onset CD (n = 196)
Sex, M/F 148/185 71/66 77/119 311/171
Age, median (interquartile range) 21 (14-30)1 14 (12-16)1 28 (23-35)1 12 (7-34)2
1: Age at diagnosis
2: Age at enrolmentHradsky et al. BMC Medical Genetics 2010, 11:91
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Results
Crude associations
The frequencies of the variants and respective OR are
listed in T able 3. No crude associations with CD were
found for the tested SNPs under the log-additive or dom-
inant models. The genotype distributions in control sub-
jects conformed to Hardy-Weinberg equilibrium in all
SNPs (p > 0.20) except the rs1427676 (p = 0.014 in exact
tests) which was therefore excluded from all further anal-
yses.
As the part of chromosome under the CTLA4 gene is
divided into the several blocks [16] we performed a hap-
lotype analysis using the five SNPs; no crude association
with CD was observed (data not shown).
Interaction of the CTLA4 SNPs with variants in IL23R and 
NOD2
We then tested possible interactions between variants in
the CTLA4 and polymorphisms in other genes previously
associated with CD: NOD2  gene p.Leu1007fsX1008
(c.3020insC), IL23R gene rs11209026 (c.1142G > A) [6,7],
see Figure 1. This was done in dominant models using an
R-project package 'SNPassoc' version 1.5-2 [24]. Signifi-
cant interactions were observed between the three
CTLA4  variants (CT60, JO31, JO27-1) and NOD2
p.Leu1007fsX1008, and the same variants in the CTLA4
and IL23R rs11209026.
For a quantification of the CTLA4 association stratified
by the above NOD2 and IL23R polymorphisms see Table
4 a Table 5: the minor alleles of the CT60, JO31 and JO27-
1 within the CTLA4 modified the risk of Crohn's disease
in the stratum of subjects carrying the frameshift inser-
tion p.Leu1007fsX1008 in NOD2, while no perceivable
effect of CTLA4  was found in the stratum of
p.Leu1007fsX1008 wild-type homozygotes. Similarly, the
three  CTLA4  variants clearly, albeit moderately,
decreased the risk of CD in the stratum of subjects carry-
ing minor alleles of rs11209026 within the IL23R (G/A
and A/A), while no effect was observed in the IL23R wild-
type homozygotes. The effect was observable also for the
haplotype consisting of the three minor alleles of the vari-
ants in tight linkage disequilibrium, the CT60 "A", JO31
"T", JO27-1 "G" haplotype.
Table 2: Clinical characteristics of patients
Total
(n = 333)
Pediatric-onset CD
(n = 137)
Adult-onset CD
(n = 196)
Age at diagnosis
A1 (<17 years) 111 111 0
A2 (17 - 40 years) 190 26 164
A3 (>40 years) 32 0 32
Localization
L1 (terminal ileum) 71 (21%) 23 (17%) 48 (25%)
L2 (colon) 50 (15%) 13 (9.5%) 37 (19%)
L3 (ileocolon) 208 (63%) 101 (74%) 107 (55%)
L 1-3 not determined 4 0 4
L4 (Upper GI)1 56 (17%) 20 (15%) 36 (18%)
Disease behavior
B1 (nonstricturing/nonpenetraiting) 138 (42%) 79 (59%) 59 (30%)
B2 (stricturing) 129 (39%) 34 (25%) 95 (49%)
B3 (penetrating) 62 (18%) 21 (16%) 41 (21%)
B 1-3 not determined 4 3 1
B4 (perianal disease) 109 (33%) 32 (23%) 77 (39%)
Extraintestinal manifestation2 53 (16%) 21 (15%) 32 (17%)
Need for surgery3 173 (52%) 41 (30%) 132 (68%)
1: GI: gastrointestinal.
2: Either of: peripheral arthritis, ankylosing spondylitis, sacroilitis, episcleritis and iritis, erythema nodosum, pyoderma gangrenosum, or 
sclerosing cholangitis.
3: Abdominal surgery for complication of CD (resection)Hradsky et al. BMC Medical Genetics 2010, 11:91
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Genotype - phenotype analysis
Using a case-only design, we tested whether the pheno-
typic characteristics of the patients are dependent on car-
riage status of the minor alleles at CTLA4 variants.
Table 6 shows logistic regression with the outcomes of
clinical characteristics and the three CTLA4 variants and
the haplotype as the predictors. The pediatric-onset
patients differed to the adult-onset patients in their fre-
quencies of the minor allele at the CT60 (74% versus 63%,
p = 0.03). The CT60, JO31 and JO27-1 SNPs, as well as
their "ATG" haplotype retained their associations with the
age at diagnosis after adjustment to the effect of the
NOD2  variant (p.Leu1007fsX1008). No difference
between pediatric and adult-onset group was found for
the other two variants in the CTLA4  gene, data not
shown.
The CTLA4 variants were weakly associated with the
ileal-only (L1) and ileocolonic involvement (L3) in a dom-
inant manner, while no association was observed with
any of the remaining clinical characteristics: localization
in the upper gastrointestinal tract, the stricturing or pen-
etrating behavior of the disease, perianal disease,
extraintestinal manifestation, or the need for abdominal
surgery (data not shown).
Discussion
The immunologic importance of the CTLA4 gene is in
striking contrast to the lack of knowledge on the func-
tional relevance of its numerous polymorphisms. Conse-
q u e n t l y ,  m a n y  g r o u p s  h a v e  i n v e s t i g a t e d  v a r i o u s
polymorphisms located within various regions of the
gene. The first published study on CTLA4 variants in CD
investigated the g.49A > G (rs231775) and g.-318C > T
Table 3: Distribution of genotypes of the studied CTLA4 polymorphisms1
Variants Genotype frequency
cases n = 333, controls n = 482
Dominant model2 Log-additive model2
rs736611 T/T T/C C/C Genotype T/C + C/C Allele C
CD 37% 48% 15% 63% 39%
Controls 34% 48% 18% 66% 42%
OR (95%CI) 0.89 (0.67 - 1.19) 0.86 (0.70 - 1.05)
g.49A > G (rs231775) A/A A/G G/G Genotype A/G + G/G Allele G
CD 41% 46% 13% 59% 36%
Controls 40% 44% 16% 61% 38%
OR (95%CI) 0.85 (0.63 - 1.14) 0.89 (0.72 - 1.09)
CT60 (rs3087243) G/G G/A A/A Genotype G/A + A/A Allele A
CD 33% 48% 19% 68% 43%
Controls 35% 48% 17% 65% 41%
OR (95%CI) 1.11 (0.82 - 1.50) 1.10 (0.90 - 1.35)
JO31 (rs11571302) G/G G/T T/T Genotype G/T + T/T Allele T
CD 29% 50% 21% 71% 46%
Controls 31% 49% 20% 69% 44%
OR (95%CI) 1.12 (0.82 - 1.53) 1.09 (0.89 - 1.34)
JO27-1 (rs11571297) A/A A/G G/G Genotype A/G + G/G Allele G
CD 29% 49% 22% 72% 47%
Controls 30% 50% 20% 70% 45%
OR (95%CI) 1.12 (0.82 - 1.53) 1.11 (0.91 - 1.36)
1: the rs1427676 polymorphism was excluded from the analyses as its distribution among healthy population did not conform to Hardy - 
Weinberg equilibrium.
2: Adjusted by genderHradsky et al. BMC Medical Genetics 2010, 11:91
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(rs5742909) in the Dutch and the Chinese populations,
finding only an association with the age of onset [18].
Similarly, in a Hungarian work, no association of g.49A >
G with CD was detected [21]. Since the work by Ueda et
al [16] had been published on dissecting the association
of  CTLA4  with immunopathological diseases, further
investigators focused on the CT60 polymorphism. This
variant was studied in the Japanese [19] and the Spanish
[20] populations, however no crude association with CD
was detected. The G/G genotype of g.49A > G was associ-
ated with penetrating form of CD in the Japanese dataset
[19]. No association within 2q33 chromosomal region has
been found by genome-wide studies [4,5,8-12].
Thus, compelling evidence has been gathered against
simple association of the disease itself with the polymor-
phisms of CTLA4. In line with these findings, we
Figure 1 SNPs interaction in the dominant model. The upper triangle in matrix from this function contains the p values for the interaction (epista-
sis) log-likelihood ratio test (LRT). The diagonal contains the p values from LRT for the crude effect of each SNP. The lower triangle contains the p values 
from LRT comparing the two-SNP additive likelihood to the best of the single-SNP models [24]. P value of interactions: * P < 0.05; ** P < 0.01; *** P < 
0.001.Hradsky et al. BMC Medical Genetics 2010, 11:91
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observed no crude association unless further genetic fac-
tors were taken into account. However, when CTLA4 was
considered as a modifier of the effects conferred by the
NOD2 and IL23R genes, possible interactions substanti-
ated. Interactions in multifactorial immunopathological
diseases are not infrequent: in CD, the interactions with
the  NOD2 gene were detected in the IBD5 locus [25],
IBD6 locus [15], TNFA [26], DLG5 [27], ATG16L1[28],
IL23R [29], TLR4 [30] and in CD14 [30]. The interaction
was also found between IBD5 locus and IL23R [31] and
between Toll-like receptor-9 polymorphisms and variants
in NOD2 and IL23R [32].
The interactions we found for the CT60, JO31, JO27-1
variants of CTLA4  (or their haplotype) with the
p.Leu1007fsX1008 variant of NOD2 may imply that the
effect of the strongest risk variant within the NOD2
(p.Leu1007fsX1008) can be expressed better on the back-
ground of the common CTLA4 haplotype. This is sugges-
tive of a complex pattern of gene-gene interaction that
may merit pursuing further functional studies. Similarly,
the risk haplotype of CTLA4 also interacts with the IL23R
protective variants. This rather weak interaction can be
also due to the relatively limited size of the dataset.
In addition to the modifying effect on the risk of the
disease itself, we observed an association with the age at
onset and the disease subphenotypes. Indeed, the impact
of genetic factors in early-onset patients with CD seems
to be stronger than in adult-onset patients (reviewed by
de Ridder L et al. [33]). In our dataset, the age at diagnosis
was associated with CT60, JO31 and JO27-1. Influence of
CTLA4 variants on the age at diagnosis has been previ-
ously described by Xia et al, although with a different
SNP (g.-318C > T) [18]. Moreover, their patients were
divided into groups where 40 years of age was the cut off,
not 18 years as in our study.
The CTLA4 was associated with the ileal and ileoco-
lonic involvement in our case set: up to our knowledge,
this is the first time when localization of CD is influenced
by any variant within CTLA4. It should be however noted
that these associations are weak, merit further investiga-
tion in other populations, and their clinical relevance can
be only hardly envisaged. The ileal form of disease has
been shown more common in adult-onset patients and
more common in patients carrying minor variants of the
NOD2 gene. A possible explanation of the association of
CTLA4 with localization of disease might be found in the
interaction between CTLA4 and NOD2 gene.
Similarly to Machida et al [19] we also tested whether
the g.49A > G variant influences the occurrence of pene-
trating disease, but we were not able to confirm this asso-
ciation. However, the genetic background between
Japanese and Czech populations differs markedly.
Table 4: Stratified analysis of the effect conferred by the CTLA4 CT60, JO31 and JO27-1 variants
NOD2 stratum
defined using the 
Leu1007fsX1008 
polymorphism 1)
CT60 (rs3087243),
A carriage rate
(genotypes A/G, A/A)
JO31 (rs11571302),
T carriage rate
(genotypes G/T, T/T)
JO27-1 (rs11571297),
G carriage rate
(genotypes A/G, G/G)
Haplotype "ATG" 4
NOD2 "+"
cases, n = 108 67 (62%) 69 (64%) 70 (65%)
controls, n = 48 38 (79%) 40 (83%) 42 (88%)
OR (95%CI) 2) 0.43 (0.19-0.95) 0.35 (0.15-0.83) 0.26 (0.1-0.68) 0.62 (0.37 - 1.05)
NOD2 "wt/wt"
cases, n = 224 157 (70%) 166 (74%) 168 (75%)
controls, n = 434 277 (64%) 292 (67%) 294 (68%)
OR (95%CI) 2) 1.33 (0.94-1.88) 1.37 (0.96-1.96) 1.42 (0.99-2.03) 1.21 (0.96. - 1.53)
Heterogeneity between
NOD2-defined strata 3)
p = 0.011 p = 0.0042 p = 0.0011 p = 0.043
Strata of the risk conferred by the p.Leu1007fsX1008 polymorphism of the NOD2 gene: the effect of CTLA4 is apparent in the stratum with an 
increased NOD2-associated risk
1) NOD2 "+": homozygous or heterozygous for the minor allele at the p.Leu1007fsX1008 polymorphism; NOD2 "wt/wt": wild-type homozygote at 
the p.Leu1007fsX1008 polymorphism. The NOD2 "+" category is associated with an increased risk of OR = 4.36, 95%CI 2.95 - 6.49 as compared to 
"wt/wt" category.
2) OR for the effect of the polymorphism in the specific stratum (NOD2"+" and NOD2"wt/wt"), adjusted for the effect of the IL23R p.381Gln variant 
and p.Gly908Arg, p.Arg702Trp in the NOD2 gene. Results significant at p < 0.05 are in bold.
3) Heterogeneity in the effect conferred by the CTLA4 polymorphisms was assessed between NOD2-defined strata using the Mantel-Haenszel 
test of homogeneity.
4) The implemented expectation-maximization algorithm did not allow individual imputation and counting of haplotypes.Hradsky et al. BMC Medical Genetics 2010, 11:91
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Conclusions
We present a study of genetic association of polymor-
phisms within the CTLA4 gene with CD and its subphe-
notypes, using a representative set of markers previously
reported from other studies. We observed interactions of
the CTLA4 haplotype with variants in NOD2 and IL23R
genes, and detected an effect of three variants of the
CTLA4 on the age at diagnosis and localization of the dis-
ease.
Table 5: Stratified analysis of the effect conferred by the CTLA4 CT60, JO31 and JO27-1 variants
IL23R stratum
defined using the 
p.Arg381Gln 
polymorphism 1)
CT60 (rs3087243),
A carriage rate
(genotypes A/G, A/A)
JO31 (rs11571302),
T carriage rate
(genotypes G/T, T/T)
JO27-1 (rs11571297),
G carriage rate
(genotypes A/G, G/G)
Haplotype "ATG" 4
IL23R "-"
cases, n = 21 10 (48%) 10 (48%) 10 (48%)
controls, n = 50 42 (84%) 40 (80%) 40 (80%)
OR (95%CI) 2) 0.23 (0.07-0.71) 0.26 (0.08-0.85) 0.24 (0.07-0.79) 0.30 (0.11 - 0.81)
IL23R "wt/wt"
cases, n = 312 214 (69%) 224 (72%) 227 (73%)
controls, n = 432 276 (64%) 292 (68%) 296 (69%)
OR (95%CI) 2) 1.26 (0.91-1.74) 1.22 (0.87-1.71) 1.21 (0.86-1.69) 1.20 (0.96 - 1.51)
Heterogeneity 
between
IL23R-defined strata 3)
p = 0.0061 p = 0.011 p = 0.011 p = 0.030
Strata of the risk conferred by the p.Arg381Gln polymorphism of the IL23R gene: the effect of CTLA4 is apparent in the stratum with an IL23R- 
associated protective effect
1) IL23R "-": homozygote or heterozygote for the IL23R p.381Gln allele; IL23R "wt/wt": wild-type homozygote at the p.Arg381Gln 
polymorphism. The IL23R "-" category is associated with a decreased risk of OR = 0.58, 95%CI 0.32 - 1.00 as compared to the "wt/wt" category.
2) OR for the effect of the polymorphism in the specific stratum (IL23R "-" or IL23R "wt/wt"), adjusted for the effect of p.Leu1007fsX1008, 
p.Gly908Arg, and p.Arg702Trp in the NOD2 gene. Results significant at p < 0.05 are in bold.
3) heterogeneity in the effect conferred by the CTLA4 polymorphisms was assessed between IL23R-defined strata using the Mantel-Haenszel 
test of homogeneity.
4) The implemented expectation-maximization algorithm did not allow individual imputation and counting of haplotypes.
Table 6: Genotype-phenotype analysis1
Outcome CT60 (rs3087243)
allele A
JO31 (rs11571302)
allele T
JO27-1 (rs11571297)
allele G
"ATG" haplotype
Pediatric age at diagnosis2 1.85
(1.12 - 3.03);
p = 0.014
1.71
(1.03 - 2.85);
p = 0.035
1.70
(1.02 - 2.84);
p = 0.039
1.52
(1.09 - 2.11);
p = 0.014
Ileal involvement (L1) 0.41
(0.24 - 0.70);
p = 0.0012
0.45
(0.26 - 0.78);
p = 0.0052
0.43
(0.24 - 0.74);
p = 0.0027
0.70
(0.47 - 1.05);
p = 0.081
Ileocolonic involvement (L3) 3 1.97
(1.21 - 3.19);
p = 0.0059
1.91
(1.16 - 3.13);
p = 0.010
1.94
(1.18 - 3.20);
p = 0.0090
1.54
(1.09 - 2.17);
p = 0.014
1: OR with their 95%CI come from logistic regression analysis using dominant models, with the clinical phenotype as an outcome and CTLA4 
CT60, JO31, JO27-1 minor variants and ATG haplotype as predictors; the models are adjusted for the p.Leu1007fsX1008 variant in the NOD2 gene.
2: Patients having been diagnosed before or at the age of 18 years.
3: Further, we tested interaction between NOD2 p.Leu1007fsX1008 variant and the CTLA4 ATG haplotype on development of L3. Comparing to 
wild haplotype on the background of the ATG haplotype the association of p.Leu1007fsX1008 NOD2 high risk variant was significantly weaker. 
P-value of the interaction between ATG haplotype and NOD2 p.Leu1007fsX1008 in the development of L3 was estimated 0.026.Hradsky et al. BMC Medical Genetics 2010, 11:91
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